- In August 2023, Alkermes, announced a settlement regarding a Teva-related patent dispute over Vivitrol (naltrexone for extended-release injectable suspension). This development involves resolving a legal dispute between Alkermes and Teva Pharmaceutical Industries Ltd. concerning the Vivitrol patent. Under the settlement, Teva will be allowed to launch its generic version of Vivitrol in 2026, contingent upon specific conditions. This agreement benefits Alkermes by providing financial compensation and clarity over its patent rights, while Teva gains access to the generic market in the future, offering patients more affordable options for opioid use disorder and alcohol dependence treatment.
- In July 2023, Titan Pharmaceuticals, Inc., announced the sale of certain ProNeura-related assets. This development involves the sale of its ProNeura business to another company, which will continue to focus on developing and commercializing the ProNeura implant. This transaction aims to streamline Titan Pharmaceuticals’ operations and enhance its strategic focus. The sale is expected to benefit the company by allowing it to concentrate on its core drug development pipeline, while the buyer will work to expand the reach and availability of the ProNeura technology, providing better treatment options for patients.
- In March 2023, Indivior PLC announced the completion of its acquisition of Opiant Pharmaceuticals, Inc. This strategic acquisition allows Indivior to expand its portfolio in the treatment of opioid use disorder and addiction. The acquisition includes Opiant's pipeline of innovative therapies, including nasal naloxone, which is designed to reverse opioid overdose. This development will benefit Indivior by enhancing its ability to offer a broader range of addiction treatment options and strengthen its position in the opioid use disorder market, ultimately improving patient outcomes with more accessible and effective treatment solutions.
